First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX (HORIZON III)

Clinical Trial ID NCT00384176

Rank	Title	Journal	Year	PubWeight™‹?›
1	Anti-VEGF therapies in the clinic.	Cold Spring Harb Perspect Med	2012	1.20
2	Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.	Br J Cancer	2013	1.08
3	Overcoming resistance to antiangiogenic therapies.	Oncologist	2012	1.05
4	Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy.	J Hematol Oncol	2012	1.01
5	Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.	Clin Colorectal Cancer	2009	1.00
6	Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?	Cancer Manag Res	2013	0.88
7	Molecular profiling of childhood cancer: Biomarkers and novel therapies.	BBA Clin	2014	0.86
8	Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives.	World J Gastroenterol	2013	0.85
9	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.	Ther Adv Med Oncol	2012	0.81
10	Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer.	Onco Targets Ther	2012	0.78